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Recent data suggest that Pancreatic Neuroendocrine Tumours (PanNETs) originate from α-
or β-cells of the islets of Langerhans. The majority of PanNETs are non-functional and do not
express cell-type specific hormones. In the current study we examine whether tumour DNA
methylation (DNAme) profiling combined with genomic data is able to identify cell of origin
and to reveal pathways involved in PanNET progression. We analyse genome-wide DNAme
data of 125 PanNETs and sorted α- and β-cells. To confirm cell identity, we investigate ARX
and PDX1 expression. Based on epigenetic similarities, PanNETs cluster in α-like, β-like and
intermediate tumours. The epigenetic similarity to α-cells progressively decreases in the
intermediate tumours, which present unclear differentiation. Specific transcription factor
methylation and expression vary in the respective α/β-tumour groups. Depending on DNAme
similarity to α/β-cells, PanNETs have different mutational spectra, stage of the disease and
prognosis, indicating potential means of PanNET progression.
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Pancreatic neuroendocrine tumours (PanNETs) are tumoursof the islets of Langerhans. The cell of origin is unclear, andmechanisms associated with progression are largely
unknown. Surgery is currently the only curative option; however,
5-year disease free survival is ~50% in patients following an R0
resection1. To date, there is no validated risk prediction tool to
accurately guide follow-up and select patients at high risk of
recurrence who might benefit from adjuvant therapy2. PanNETs
are clinically and genetically heterogeneous; ~40% of patients
present with mutations in either DAXX or ATRX and MEN1,
which encode for proteins involved in epigenetic regulation3.
PanNETs with mutations in DAXX or ATRX have a shorter
disease free survival compared to wild-type tumours4.
The islets of Langerhans include five different cell types pro-
ducing specific hormones: glucagon is produced by α-cells,
insulin by β-cells, somatostatin by δ-cells, ghrelin by ε-cells
and pancreatic polypeptide by PP-cells. Only a minority of
PanNETs are functional, secreting inadequate hormones that
lead to clinical syndromes. The majority of functional PanNETs
are insulinomas. Whether functional tumours and non-
functional tumours originate from the same cell type remains
uncertain.
Recent studies of gene expression and master regulator ana-
lysis alongside investigation of super-enhancer signatures have
suggested both α- and β-cells as two possible cells of origin for
non-functioning (NF)-PanNETs5–8. On the other hand, Sada-
nandam et al. reported that a group of aggressive PanNET,
namely, “metastasis-like primary”, have a phenotype char-
acterised by “stemness” transcripts (in terms of pancreatic
progenitor-specific genes) compared to well-differentiated
tumours, also suggesting a common progenitor cell origin5.
Similarly, based on the identification of master regulator pro-
teins, dedifferentiation and acquisition of stem cell character-
istics seem to be one of the pathways associated with tumour
progression6.
The cell of origin in cancer refers to the normal cell that
acquires the initial cancer-promoting genetic hit(s). During
development, cell lineage fate is determined by cell-type-specific
transcription factor (TF) expression, which in turn is dependent
on the type of epigenetic markers that are located at the relative
regulatory regions (e.g. super-enhancer activation)9. The five
endocrine cell types derive from a common endocrine precursor,
which has segregated from a ducto-endocrine bipotent cell
population10. The TFs, Pax4 (Paired Box 4) and Arx (Aristaless
Related Homeobox), are required for β- and α-cell fates, respec-
tively. Lineage decision is determined via cross-inhibitory inter-
actions11. Pdx1 (Pancreatic And Duodenal Homeobox 1)
expression becomes restricted to cells at the stage of initiating
insulin expression and, in the pancreatic islets of Langerhans,
remains up-regulated exclusively in β-cells12. Integrative analysis
of human epigenomes including histone modification patterns,
DNA accessibility, DNA methylation and RNA expression has
revealed that disease- and trait-associated genetic variants are
enriched in tissue-specific epigenomic marks13. In the context of
tumour biology, epigenetic states of cell lineages shape the vul-
nerability for specific genetic alterations and thereby reveal a
distinct class of lineage-associated cancer genes14–16. Therefore,
determining the cell of origin is crucial to understand tumour
specific carcinogenesis and progression17. Cancer DNA-
methylation profiles have been utilised to determine the cell of
origin of several tumour types18,19. In this study, we set out to
determine the putative cell of origin of PanNETs through DNA-
methylation analysis. We also identified genetic driver mutations
specific to different cells of origin which are related to clinical
outcome. Based on our findings we propose a new model of
PanNET origin and progression.
Results
DNA-methylation signature of PanNETs showed similarities to
α- and β-cells. We analysed the methylomes of 125 PanNETs and
of isolated normal α- and β-cells20 to determine which of these is
the cell of origin (cohort details are summarised in Table 1 and
reported in Supplementary Data 1). All samples were processed
on the HumMeth450 BeadChip platform (Illumina HM450). We
carried out the assays for 45 primary PanNETs (UCL and UB
cohorts), while DNA-methylation data for the additional
80 samples (ICGC cohort) were produced by the International
Cancer Genome Consortium (ICGC). A flow chart of the analysis
performed is provided in Supplementary Fig. 1. The comparison
between sorted normal α- (n= 2) and β-cells (n= 2) resulted in
2703 differentially methylated CpG sites (adj. p value < 0.001 and
more than 20% difference between the mean β-values of each
group—|Δβ| > 0.2, Supplementary Data 2), 2131 of them were
retained, after filtering and normalization, in the tumour
Table 1 Patient cohort used for methylome analysis
(cohort 1).
UniBern cohort UCL cohort ICGC cohort Total
Total number of
patients
26 19 80 125
Sex
Females 10 12 31 53
Males 16 7 49 72
Grade (WHO
2010)
G1 6 8 32 46
G2 20 11 48 79
Tumour Stage
(AJCC 8th ed.)
T1 3 3 10 16
T2 8 10 18 36
T3 15 4 26 45
T4 0 0 26 26
No data 0 2 0 2
N stage
N0 10 7 42 57
N1 13 4 36 52
No data 3 8 2 13
M stage
M0 12 2 67 80
M1 10 1 13 24
No data 4 16 0 21
DAXX/ATRX
Wild-type 8 11 53 72
Mutated 18 7 27 52
Not applicable 0 1 0 1
ALT
Negative 8 11 42 61
Positive 16 3 29 48
Not Applicable 2 5 9 16
MEN1 (somatic
mutations)
Wild-type 12 13 49 74
Mutated 14 6 31 51
Hormone
functionality
F-PanNETs 8 2 12 22
NF-PanNETs 18 0 68 86
Not Applicable 0 17 0 17
Syndromic—
MEN1
0 2 3 5
Median follow-
up time (mths)
83 40 37.5 37.9
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DNA-methylation table (including the values of methylation for
363,665 CpG sites and 125 samples). Phyloepigenetic analysis of
the 2131 identified CpG sites using either normal β- or normal α-
cells as roots, indicated clear hierarchical relationships between
normal cells and tumour specimens (Fig. 1a, Supplementary
Fig. 2a). We defined PanNETs that grouped together with normal
α- or β-cells as α-like or β-like PanNETs, respectively (Fig. 1a and
Supplementary Data 1). We compared these phyloepigenetic
groups to cell type similarity obtained from cell-type deconvo-
lution analysis: using the algorithm of Houseman et al.21 (a
method similar to regression calibration), we inferred the con-
tribution of DNA-methylation profiles of sorted normal pan-
creatic cell types (α, β, acinar, ductal20, fibroblastic pancreatic


























































































Group3 (recurrent whole chromosomal loss)
Group2 (aneuploidy - loss and gain)
Group1 (limited number of CN events)
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PanNETs (Supplementary Fig. 2b). Notably, phyloepigenies of
tumours that were close to normal α/β-cells showed similarity
>65% and an average of 72 and 73% of similarity to α and β-cells,
respectively (SD for α-like ±15% and for β-like ±9%, Supple-
mentary Data 1). T-distributed stochastic neighbour embedding
(t-SNE) analysis, using the identified 2131 CpGs and including
normal cells and PanNET samples, showed a consistent segre-
gation, according to the groups defined via similarity scores and
phyloepigeny analysis (Supplementary Fig. 2c). These results
showed at least two groups of tumours with clear and high
similarity to either α- or β-cells (Fig. 1a, Supplementary Fig. 2a
and Supplementary Fig. 2c). The majority of tumours, however,
revealed an intermediate differentiation profile. Intermediate
tumours clustered between α- and β-cells and showed weak
similarities to α- (as average 51 ± 20% of similarity) and very
weak similarity to β-cells (as average 14 ± 16% of similarity),
respectively.
Regulatory sites of α- and β-cell-specific transcription factor
checkpoints were differentially methylated. We used previously
published data to select 10 α- and 10 β-cell-type associated24 TF
checkpoints (genes reported to function as RNA polymerase II—
regulating DNA-binding transcription factors and included in the
TFcheckpoint database25). As methylation of enhancers and
regulatory chromatin states are important elements of epigenetic
guidance of cell states, these regions were selected based on
integrated ChIP-seq, DNA-methylation and ATAC-seq experi-
ments of normal islets26. After selection of regulatory regions on
autosomal chromosomes, probes retained for the analysis were
related to 7 α-specific and 9 β-specific TF checkpoints (listed in
Table 2). Specifically, the selection resulted in 49 CpGs for the α-
cell TF checkpoints and 51 CpGs for the β-cell TF checkpoints
(list and relative features of the selected CpG sites are reported in
Supplementary Data 3 and 4). Consensus clustering of the 125
PanNETs according to each cell-specific TF-checkpoint signature
(k-means= 2, reflecting one cell-type enriched cluster and one
nonspecific cluster) showed clear and consistent cluster forma-
tion. The β-specific cluster separated very clearly and included all
the β-like tumours. Interestingly, the α-specific cluster showed a
broader inclusion of tumours. While the α-like (phyloepigenies
with >65% of similarities to alpha cells) tumours clustered mainly
close to each other on one extreme, intermediate PanNETs were
included to this group as well but progressively distant from the
α-like tumours (Fig. 1b).
Alpha-, intermediate and β-like PanNETs have distinct genetic
aberrations. We screened MEN1, DAXX and ATRX genes for
mutations and we classified DAXX/ATRX mutated samples, those
tumours which are mutated in either or both the genes. Within
the β-like PanNETs 13 of 14 were MEN1/DAXX/ATRX wild-type.
Alpha-like PanNETs were enriched for tumours with only MEN1
mutations (11/19), 8/19 α-like PanNETs were MEN1/DAXX/
ATRX wild-type and none harboured MEN1 and DAXX/ATRX
mutations (Fig. 1a and Supplementary Data 1). Sixty-seven per-
cent (62/92) of intermediate PanNETs harboured mutations in
MEN1 and/or DAXX/ATRX genes (intermediate-ADM) while the
rest were wild-type (intermediate-WT) (Fig. 1a and Supplemen-
tary Data 1).
Inferred copy-number aberrations (CNAs) from HM450 signal
intensities stratified the tumours into three subtypes (Supple-
mentary Fig. 3e). Copy-number aberration (CNA) group 1 had
few copy-number events. Group 2 included samples with gains
and losses. CNA group 3 showed the largest number of CNAs,
predominantly with loss of multiple chromosomes (Supplemen-
tary Fig. 3e). Notably, α- and β-like tumours presented few copy-
number events while the intermediate PanNETs showed increas-
ingly copy-number events (Fig. 1a).
DNA-methylation signatures associated with cell of origin
correlated with transcription factor expression. To confirm the
methylation-based cell lineage similarity, we performed immu-
nostaining for ARX and PDX1 on a subset of samples for which
formalin-fixed paraffin-embedded tissue was available (n= 61,
Supplementary Data 1; for n= 39 cases also glucagon and insulin
expression was assessed; results are reported in Supplementary
Data 1). Nuclear positivity for ARX and PDX1 was present in the
expected distribution in normal islets (Supplementary Fig. 4). We
identified ARX positivity in 47/61 PanNETs (Supplementary
Data 1 and Fig. 1c). As expected, the majority of insulinomas
expressed PDX1, except one malignant and one DAXX/ATRX
mutated insulinomas, which showed nuclear positivity for ARX
but not for PDX1 (Supplementary Data 1 and Fig. 1c). None of
the 61 tumours were double positive and only four PanNETs were
double negative (Supplementary Data 1 and Fig. 1c).
Immunohistochemistry confirmed the same group segregation
as was determined by the methylation analysis: (1) α-like tumours
expressed ARX (Fig. 1c, Supplementary Data 1), (2) β-like
tumours expressed PDX1, with only one sample positive for ARX
and PDX1 negative (Fig. 1c, Supplementary Data 1), (3) 38/44
(86%) intermediate PanNETs were positive for ARX and only two
cases were PDX1 positive and ARX negative. A minority of
Fig. 1 PanNET methylomes resemble distinct endocrine cell lineages. a Phyloepigenetic analysis of PanNET (n= 125) and normal α- and β-cell samples
(n= 2 for each cell type). A rooted tree was created with an arbitrary chosen β-sample as the root and selecting the differentially methylated CpGs
between sorted normal α- and β-cell samples (n= 2131, adj. p value < 0.001 and |Δβ | > 0.2). Blue and orange scales show the degree of similarity of each
PanNET sample to α- and β-cells, respectively. The degree of similarity was calculated via DNA-methylation cell-type deconvolution comparing tumour
methylomes to sorted normal α- and β-cell methylomes. Each line represents a patient. Clinical and molecular features for each sample are indicated.
b Consensus clustering of the 125 PanNETs according to the α- and β-cell-specific TF-checkpoint methylation sites (49 CpGs for β-cells and 51 CpGs for α-
cells). The k mean value was set to 2. Consensus cluster correlation is indicated according to the blue scale as depicted. Fractions of similarity to α- and β-
cells for each sample are reported at the bottom of each matrix according to the blue and orange scales. Similarly, the cell-type-specific tumour groups are
reported for each sample in blue (α-like), orange (β-like), and white (intermediate). c Schematic overview of the PanNET subtypes. Doughnut chart for all
samples showing cell-specific PanNET subtypes, ARX and PDX1 expression, MEN1 and DAXX/ATRX mutations.
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intermediate tumours (4/44, 9%) were negative for both PDX1
and ARX (Fig. 1c, Supplementary Data 1).
These results indicate that cell type assigned by DNA
methylation, corresponded to the cell type assigned by TF
expression.
PDX1 and ARX immunopositivity correlates with mutation
spectrum of PanNETs in an independent cohort. To validate
the correlation of putative cell of origin to mutational status, we
performed immunostaining for ARX, PDX1, insulin, glucagon
and DAXX/ATRX on an independent cohort of 65 G1/G2 Pan-
NETs (cohort details are summarised in Table 3 and reported in
Supplementary Data 5). We scored nuclear positivity for ARX in
34 samples (52%), for PDX1 in 21 samples (32%), 3 tumours (5%)
showed strong double positivity and 13 (20%) were negative for
both TFs (Figs. 2a, b). Notably, all the DAXX/ATRX-negative
samples expressed ARX, confirming the α-like tumour suscept-
ibility for these mutations (Figs. 1a, 2c). While only a subset of
ARX+ tumours secreted glucagon (n= 7, 20% of all the ARX+
tumours, Fig. 2c), almost all the PDX1+ tumours produced
insulin (n= 18, 95% of all PDX1+ tumours, Fig. 2c).
We observed that advanced stage PanNETs either expressed
ARX or none of the TFs and often showed DAXX/ATRX loss
(Fig. 2c, Supplementary Fig. 5a and Supplementary Data 5).
Tumours positive for PDX1 had the lowest risk of relapse
(Supplementary Fig. 5b and c). However, DAXX/ATRX status did
not improve stratification of ARX+ samples for risk of relapse
(Supplementary Fig. 5b).
Epigenetic differentiation status determines clinical outcome
of PanNETs. In order to determine clinical utility, we reviewed
clinical outcome and prognosis for α-like, β-like and intermediate
tumours (from cohort 1). Fourteen of 19 α-like PanNETs were G1
and 15/19 were of low stage (T1 or T2, Fig. 1a and Supplementary
Data 1). Similarly, 7/14 β-like PanNETs were G1and 11/13 (1
without data) were T1 or T2 (Fig. 1a and Supplementary Data 1).
Only one patient with an α-like tumour and none of the patients
with a β-like tumour had relapse (Figs. 1a, 3a and Supplementary
Data 1). Tumours that belonged to the intermediate phyloepi-
genies, were instead enriched for high stage (65/91 were T3 or T4,
1 without data) and higher grade (67/92 are G2) PanNETs and
had increased relapse risk (35/67, 25 had not available data—
Figs. 1a, 3a and Supplementary Data 1). Intermediate tumours
showed generally higher Ki-67 positivity (Supplementary Fig. 6).
Disease free survival in intermediate tumours was significantly
shorter than in α-like and β-like tumours (p < 0.001, Fig. 3a). To
assess if epigenetic profile can stratify patients better than TF and
DAXX/ATRX expression we performed disease free survival
analysis on all samples where DNA-methylation and TF expres-
sion data were available. We determined time to relapse, using
either expression of ARX, PDX1 and DAXX/ATRX or the epi-
genetic status as discriminant (Fig. 3b, c). Epigenetic profiles
could predict more accurately the risk of relapse as shown in
Fig. 3b, c and Supplementary Fig. 5c.
Further, to identify a tumour dependent signature, suitable for
stratification in clinical practice, we have compared the three cell-
type specific clusters, α-like, β-like and intermediate. The
comparison revealed 6364 unique differentially methylated sites
(Supplementary Data 6–8; adj. p value < 0.001 and |Δβ| > 0.2).
Consensus clustering of the 6364 CpG sites showed the maximal
stability for k= 4 (Supplementary Fig. 7a). The existence of α-like
and β-like clusters was confirmed (Fig. 3d and Supplementary
Data 1). The intermediate subgroup was divided into two further
groups, one enriched for DAXX/ATRX/MEN1 mutations, inter-
mediate-ADM, (61/76 had mutations in at least one of the three
genes; Fig. 3d and Supplementary Data 1) and the other enriched
for DAXX/ATRX/MEN1 wild-type samples, intermediate-WT
(15/16, only 1 DAXX/ATRX mutated; Fig. 3d and Supplementary
Data 1). PanNETs included in the intermediate-ADM and
intermediate-WT showed comparable risk to relapse (Supple-
mentary Fig. 7b). To prove the stability of the signature, we
repeated the analysis including 32 new G1/G2 PanNETs, for
which DNA-methylation data were public available7 (Supple-
mentary Data 9). After filtering and normalization processes,
6359/6364 of the previously identified differentially methylated
sites were used in the consensus clustering algorithm. The results
confirmed the 4 PanNET subgroups with similar relapse risks to
the previous analysis (Supplementary Fig. 7c–e).
Discussion
This study identified at least two cells of origin for PanNETs (α-
like/β-like) and demonstrated that DNA-methylation analysis can
discriminate α-like, β-like and intermediate (-ADM and -WT)
PanNETs. Additionally, this study identified that relapses and
metastases occurred most commonly in the intermediate (-ADM
and -WT) PanNET groups.
Phyloepigenetic analysis of PanNETs, according to differen-
tially methylated CpG sites between normal α- and β- cells,
showed two clusters around normal α- and β- cells, which we
named α-like and β-like. PanNET sample segregation was
Table 3 Validation cohort (cohort 2).
Patient cohort





































Median follow-up time (mths) 55
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consistent in the t-SNE analysis. Using a similar approach, in a
recent study, methylation-based subclasses of colorectal cancer
were explained as clonal amplifications of one specific epigen-
otype, confirmed by the enrichment of different mutations in the
particular subtypes and by the investigation of methylation sig-
natures in serial tumour xenografts and derived spheroids18.
Similarly, in medulloblastoma subtypes with distinct develop-
mental origin, DNA-methylation signatures were able to stratify
tumours according to the specific subtype, to provide information
about the cell of origin and also to demonstrate acquired epige-
netic changes during tumour progression14,27,28. Even if in the
aforementioned studies tumours were not directly compared to
the putative normal cells of origin, the epigenetic and mutational
landscape of the malignancies reflected the tumour classes and
cells of origin defined via in vivo studies. Altogether the data
confirm the valuable use of DNA-methylation profiles for the
identification of tumour cells of origin.
Cell-type deconvolution analysis of methylome data from
ductal, acinar, inflammatory and pancreatic stromal cells together
with α- and β- cells found that α-like and β-like PanNETs are
largely similar (at ~73%) to α- and β- cells, respectively. This
figure is comparable to other studies: Houseman and Ince29
demonstrated the application of their algorithm to estimate
normal cell proportions in breast cancer heterogeneous tissues.
Similarly, cell-type deconvolution analysis based on DNA
methylation for mantel cell lymphoma (MCL), showed a mini-
mum of similarity between MCL and B cell samples of 40%30.
When a similar algorithm (L1-regularized logistic regression) is
used to classify cancers of unknown origin (CUPs) based on DNA
methylation, a probability >30% was used to ascribe CUPs to a
specific tumour type31. The deconvolution of the methylation
estimates for PanNETs identified two important aspects of the
tumour methylomes: that the results were not influenced by the
composition of non-tumoral cells within the PanNET samples
(Supplementary Fig. 2b) and that the composition of early stage
α-like and β-like PanNETs is abundant for either α- or β-cells
(Fig. 1a).
Analysis of methylation status of α- and β-cell-specific TF
checkpoints regulating differentiation might help to better iden-
tify the intermediate groups of PanNET. While β-like samples
separated very clearly according to β-cell TF-checkpoint methy-













































Fig. 2 Expression of ARX, PDX1, insulin, and glucagon can be used as surrogate for defining tumour cell-type specificity. a Immunostaining for the
different subtypes of PanNETs. From the top to the bottom: tumour positive for ARX and glucagon; tumour positive for ARX; double positive tumour for
PDX1 and ARX; double negative tumour for ARX and PDX1; tumour positive for PDX1 and insulin. For the TFs only nuclear staining was considered for
scoring. b Venn diagram displaying the total number of samples positive for ARX and/or PDX1or negative for both the transcription factors. c Schematic
overview of the PanNET subtypes in cohort 2. Doughnut chart for all samples showing glucagon, insulin, PDX1 and ARX positivity as well as loss of DAXX/
ATRX expression.
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remaining samples. Seventy of seventy-six intermediate-ADM
PanNETs clustered together with the α-like tumours (Supple-
mentary Data 1). Twelve of sixteen intermediate-WT PanNETs
did cluster neither with α-like nor with β-like tumours (Supple-
mentary Data 1). Additionally, intermediate-ADM PanNETs
were on average more similar to α- (53 ± 17%) than β-cells (12 ±
13%). Ninety-five percent of the intermediate-ADM tumours
were positive for ARX (36/38) and none for PDX1. This might
indicate that intermediate-ADM PanNETs are more related to α-
cells rather than β-cells. The PanNET methylation subgroups that
we have identified reflect the groups A (tumours that most likely
originate form α-cells), B (tumours that most likely originate
form β-cells) and C (tumours with intermediate phenotype)
recently described by Cejas et al., via the analysis of super-
enhancer signatures8. Comparable to our study, the analysis of TF
expression via IHC performed by Cejas et al. revealed mutually
exclusive expression of either ARX or PDX1 in the majority of the
cases. Additionally, while PDX1 expression appears to be specific
for benign and low stage tumours, ARX expression is retained at
early and at advanced stages and only DAXX/ATRX status pro-
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We identified a clear correlation between driver mutation
status and epigenetic profiles across all PanNETs. Alpha-like
PanNETs and intermediate-ADM PanNETs harboured MEN1
mutations, this is supported by the results of Chan et al. and Cejas
et al.7,8. Fifty-eight percent of the clinically indolent α-like Pan-
NETs were characterized by MEN1 mutations only. MEN1
inactivation, is an early event in PanNET progression32,33, which
enhances endocrine cell proliferation34, hence it might be a
tumour initiating event for the α-like PanNETs and for the
intermediate-ADM. In turn Intermediate-ADM PanNETs might
progress upon acquisition of DAXX/ATRX inactivation. In
addition, CNA increased from α-like and β-like PanNETs to
intermediate-ADM tumours. All these data together suggest a
potential progression from α-like to intermediate-ADM PanNET.
We cannot exclude, however, that the two intermediate PanNET
clusters might originate from putative endocrine precursor cells.
During islet cell development, ARX is already expressed in
endocrine precursors11, furthermore different endocrine cell
types, as α- and γ-cells share ARX expression24,35. Conversely
PDX1 expression is restricted to differentiated β-cells, within the
endocrine lineages12. Of the intermediate-WT tumours for which
IHC data were available (n= 6), two were positive for PDX1, two
for ARX and two were negative for both TFs. Additionally,
similarly to the β-like tumours, intermediate-WT PanNETs
showed only few copy-number events (group 1, Supplementary
Data 1). Currently our data only weakly support progression from
β-like to intermediate-WT PanNETs, nevertheless this possibility
cannot be excluded.
While the vast majority of β-like PanNETs expressed PDX1
and insulin, the two malignant (N1 and/or M1) insulinomas of
our cohort, showed one intermediate-ADM (DAXX/ATRX
mutated) and one α-like (DAXX/ATRX wild-type) methylation
signatures (Supplementary Data 1). Only for the intermediate-
ADM insulinoma, data on PDX1 and ARX were available; it
resulted positive for ARX, and negative for PDX1 expression.
Accordingly, the only malignant insulinoma of the Chan et al.
cohort was mutated for ATRX and clustered with the
intermediate-ADM tumours. In line with this observation, a
recent study including 37 sporadic insulinomas (35 primary and
2 liver metastases) showed that all the five insulinomas which
metastasized were ARX positive and 4/5 had ALT activation
(3 primary and 2 liver metastases)36. These data suggest that
malignant insulinomas may arise from α-cells or stem-cells rather
than β-cells. Under certain conditions and stimuli α-cells are able
to trans-differentiate into β-cells37–41. Additionally, α-cell-specific
Men1 knockout in mice leads to the development of glucagono-
mas, which evolve into mixed glucagonoma/insulinoma to ulti-
mately become insulinomas, possibly via trans-differentiation of
the Men1-deleted α-cells42,43. Beta-like and/or PDX1 positive
tumours are strongly enriched for benign insulinomas in both the
first and second cohort. They generally show no mutations in any
of the most commonly mutated genes for PanNETs (DAXX,
ATRX and MEN1). These data confirmed the genetic difference
between non-functioning tumours and insulinomas5,44–46. Of the
thirteen wild-type PanNETs obtained from Chan et al.7, five were
included in the β-like cluster (two insulinomas and three NF-
PanNETs), six in the intermediate-WT cluster and only two in
the intermediate-ADM cluster. All the ADM-mutant PanNETs
were included in the intermediate-ADM cluster (Supplementary
Data 9). These data and the few β-like NF-PanNETs included in
the cohort 1, demonstrate that occasionally also NF-PanNETs
might originate from β-cells.
Our methylation data support the possibility of two evolu-
tionary pathways for PanNET development, originating from
α- and β-cells (Fig. 3e). Beta-like PanNETs usually manifest as
insulinomas. The α-like PanNETs are susceptible to MEN1
mutations in early tumorigenesis. Tumour progression occurs
upon DAXX/ATRX mutations, coupled with ALT activation and
a characteristic CNA profile4,47–49. Progressive loss of differ-
entiation might further predispose the tumours to enhanced
proliferation and higher cell plasticity (Fig. 3e). Alternatively or
additionally to this dedifferentiation model, potential endocrine
progenitor cells might be the cell of origin of intermediate
tumours (Fig. 3e). While CNA, genetic background and epige-
netic suggest a progression from α-cells to α-like tumours first
and then to intermediate-ADM, we do not have the same evi-
dence supporting an evolution from β-like tumours to inter-
mediate-WT, even if we cannot completely exclude it. In fact,
while a progression from β-like benign insulinoma to aggressive
intermediate-WT tumours is, based on clinical evidences, very
unlikely; a direct origin of these tumours from normal adult β-
cells or from a common progenitor is more plausible. Expression
of cell type TFs such PDX1 and ARX is equally distributed in
intermediate-WT however DNA-methylation profile indicates
similarity with β-cells (Fig. 3d and Supplementary Fig. 7d).
We acknowledge that our study is based on static observations
taken at one timepoint in each tumour’s development. Sequential
sampling or in vivo experiments would be able to determine real
time tumour evolution and would be able to address the unan-
swered questions we propose here.
Clinically α-like, β-like and intermediate tumours have different
outcomes. While α-like and β-like tumours are indolent, inter-
mediate tumours (-ADM and -WT) have high risk of relapse.
Interestingly, DAXX/ATRX status alone is not sufficient to dis-
criminate between ARX+ with high and low risk of relapse. Indeed,
in the intermediate-WT group we observed the presence of ARX+
Fig. 3 Epigenetic differentiation status defines clinically different PanNETs and draws two possible ways of PanNET evolution. a Kaplan–Meier disease
free survival of 95 patients (cohort 1) stratified according to cell-type specific methylation groups (α-like in blue, β-like in orange and intermediate in grey).
Intermediate tumours have higher risk of relapse compared to α- and β-like tumours (p value= 0.00016). In b and c disease free survival of a subset of
patients of cohort 1 (n= 50) with available data for both DNA-methylation profile and PDX1, ARX, and DAXX/ATRX IHC. In b patient stratification
according to cell-type-specific methylation groups and in c according to PDX1, ARX, and DAXX/ATRX IHC (in grey patients double negative for PDX1 and
ARX or ARX positive and negative for DAXX/ATRX, in light-blue patients double negative for PDX1 and ARX or ARX positive and DAXX/ATRX positive, in
light-orange patients double positive for PDX1 and ARX or PDX1 positive and DAXX/ATRX positive). d Consensus clustering of the 125 PanNETs according
to the 6364 differentially methylated sites between α-like, β-like and intermediate tumours (adj. p value < 0.001 and |Δβ| > 0.2). Cluster stability was
reached for k= 4 (see Supplementary Fig. 7a). Consensus cluster correlation is indicated according to the blue scale as depicted. Each column represents
one PanNET sample. Tumour mutations and cell-type subgroups are indicated according to the reported colours. e Progression model hypothesis based on
epigenetic and genetic evolution: α-like tumours originate from α-cells uponMEN1 inactivation, the progression to intermediate-ADM tumours is enhanced
by secondary events, including loss of DAXX/ATRX and chromosomal instability with recurrent LOH and activation of ALT. These events are associated to
a gradual loss of differentiation. Beta-like tumours originate from β-cells upon different genetic event and they are mainly insulinoma, usually indolent.
However, based on our data it is not possible to exclude that intermediate-WT PanNETs originate directly from β-cells or from a progenitor cell. Similarly
we cannot exclude that intermediate-ADM may originate from a precursor cell as well. Progression supported by genetic and epigenetic data is depicted by
full lines, while hypothetical progression is depicted by dotted lines.
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tumours, with high risk of relapse. Only the DNA-methylation
profile is able to separate ARX+ PanNET with low risk from high
risk of relapse. The intermediate groups of PanNET are char-
acterized by high risk of relapse but are molecularly different (ADM
and WT) (Fig. 3d and Supplementary Fig. 7d). Further work is
needed to assess whether intermediate-ADM and intermediate-WT
aggressive PanNETs have different origins or respond differently to
therapies.
DNA-methylation analysis clearly bears advantages over ChIP-
seq assays, it is easily performed on diagnostic routine FFPE
specimens. We foresee a potential clinical use of epigenetic pro-
filing for PanNETs similar to CNS tumor classification, able to
define clinically relevant groups28,50,51. In addition, DNA
methylation remains stable in circulating tumor cells (CTCs) and
cell-free DNA (cfDNA) (reviewed in ref. 52), hence might be
applied to monitor progression in individual patients in a non-
invasive liquid biopsy. DNA-methylation profiles can help in
identifying patients with risk of relapse and we envision that in
the future can help in predicting therapy response.
In conclusion DNA-methylation analysis could be easily
implemented in clinical practice to identify patients with high
relapse risk and those which might benefit from adjuvant therapy.
Methods
Patient cohorts. A cohort of primary PanNETs was assembled from two inter-
national centres; 19 samples previously analyzed53 from UCL Cancer Institute
(London, UK) and 26 from Institute of Pathology (Bern, Switzerland). All cases
were classified according to WHO 2017 criteria54. TNM staging is based on the 8th
edition UICC/AJCC. Inclusion criteria were histopathologic diagnosis of well-
differentiated G1/G2 PanNETs, availability of tissue material and sufficient tumour
purity (>70%). Fourteen of 45 tumour samples (31%) were classified as G1, 31/45
(69%) as G2 (Table 1). Two samples derived from MEN1-patients. All analyses
were performed on Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens
obtained from routine pathological work-up. Additional clinico-pathological
characteristics are reported in Supplementary Data 1. The study on this cohort was
approved by the local Research Ethics Committees (Bern: number 105/2015;
London: number 09/H0722/27). Patients recruited through the Inselspital with
operation data before 2015 did not object to use of data and biological material for
research, all patients included after 2015 did sign a written broad institutional
consent. Informed written consent for patients recruited through the Royal Free
Hospital Neuroendocrine Unit was obtained before entering the study. All samples
were fully anonymised.
Clinical and molecular data of 80 PanNETs were provided by the International
Cancer Genome Consortium (ICGC, https://icgc.org/, projects: PAEN-AU and
PAEN-IT). Cohort features are summarised in Table 1 and Supplementary Data 1.
Genomic and molecular analysis of the samples were performed within Scarpa
et al. study47.
As immunohistochemical validation cohort, 65 PanNET samples were
assembled at the Institute of Pathology (Bern, Switzerland). All cases were
reclassified according to WHO 2017 criteria54. TNM staging is based on the 8th
edition UICC/AJCC55. As for the previous cohorts, only well-differentiated G1/G2
PanNETs were included. Cohort features are summarised in Table 3 and
extensively reported in Supplementary Data 5. The study on this cohort was
performed according to the protocol approved by the ethical committee (number
105/2015) according to Swiss Human research Act. Patients with operation data
before 2015 did not object to use of data and biological material for research, all
patients included after 2015 did sign a written broad institutional consent.
A flow chart of the analysis performed on the 2 cohorts is provided in
Supplementary Fig. 1.
Immunohistochemistry (IHC) and telomeric-fluorescence in situ hybridization
(Telo-FISH). All samples were assessed for DAXX (1:40, anti-DAXX, polyclonal
rabbit; Sigma–Aldrich, St. Gallen, Switzerland) and ATRX (1:400, anti-ATRX,
polyclonal rabbit; Sigma–Aldrich) expression via IHC and ALT activation via Telo-
FISH on 2.5 µm sections prepared from a tissue microarray (TMA - Bern cohort
and validation cohort) or whole block sections (London cohort). For FISH, sections
were deparaffinised and rehydrated, slides were then boiled for 30 min in citrate
buffer, pH 7.2, and incubated for 30 min in 2 × standard saline citrate and 0.05%
Tween 20. A peptide nucleic acid (PNA) probe (telC-Alexa488; Panagene, Daejeon,
Korea) was diluted (1:10) in 70% formamide, 10 nmol/L Tris, pH 7.5. One drop of
PNA solution was spotted on hydrophobic gel bond film and mounted on a
glass slide. Samples were denatured at 85° for 4 min and incubated for 2 h at
room temperature in the dark. Following slides were washed in 60% formamide
10 nmol/L Tris, pH 7.5, for 5 min and 2 × standard saline citrate-Tween 20. Anti-
promyelocytic leukemia (PML) (antibody PG-M3; Santa Cruz, Heidelberg,
Germany) 1:100 was incubated for 1 h at room temperature and the secondary
antibody (goat-anti-mouse Alexa568; Cell Signaling, Danvers, MA) was diluted
1:500 and incubated for 1 h at room temperature in a dark chamber. One percent
4′,6-diamidino-2-phenylindole solution was incubated for 3 min at room tem-
perature. FISH was evaluated using an Olympus VS 110 Fluorescent Scanner
(Olympus, Volkestwil, Switzerland).
For the immunostainings, antigen retrieval for DAXX was performed by
heating citrate buffer at 100° for 30 min and for ATRX in 95° Tris buffer for
40 min. Primary antibody was incubated for 30 min at the specified dilutions.
Visualization was performed using the avidin-biotin complex method. For both
DAXX and ATRX scoring, only nuclear protein staining was considered positive.
Similarly, 2.5 µm sections from TMAs or whole blocks were used for ARX
(1:1500, R&D Systems, sheep, AF7068), PDX1 (1:100, R&D Systems, mouse,
MAB2419), insulin (1:12000, Sigma–Aldrich, mouse, I-2018) and glucagon
(1:20000, Sigma–Aldrich, mouse, G-2654) immunostainings. Antigen retrieval
was performed by heating Tris30 buffer at 95 °C for 30 min. The primary
antibody was incubated for 30 min at the specified dilutions. Visualization was
performed using Bond Polymer Refine Detection kit, using DAB as chromogen
(3,3′-Diaminobenzidine).
Samples showing single cell positivity of any of the TFs were finally scored as
negative, most of the cases were indeed strong positive for one of the two TFs with
only few exceptions (single cell positivity is reported for each sample in
Supplementary Data 1 and 5). Only strong positivity for insulin and glucagon was
considered for classification of the tumours as hormone producing PanNETs.
Nuclear positivity for ARX and PDX1 was first assessed on normal islets, proving
the selectivity for endocrine α- and β-cells (Supplementary Fig. 4).
The immunostaining for all antigens was performed on an automated staining
system (Leica Bond RX; Leica Biosystems, Nunningen, Switzerland).
DNA-methylation analysis. We extracted DNA from FFPE tissues according to
manufacturer recommendations (QIAamp DNA minikit, Qiagen). Serial sections
were cut and macrodissected using a razor blade upon histological evaluation (5 ×
6 µm), to make sure to achieve >70% tumour purity. We assessed DNA quality
using the Illumina FFPE QC Kit. Ligation of FFPE DNA and bisulphite conversion
were performed as described56. Efficiency of bisulphite conversion was confirmed
by quantitative PCR as previously shown56. Converted DNA was processed on the
HumMeth450 BeadChip (Illumina HM450). We analysed all the DNA-
methylation data included in this study using the ChAMP pipeline (v2.12.4, minfi
method was used for raw data loading)57–59. Filtering was performed as imple-
mented in the ChAMP pipeline60. Only probes located on autosomal chromosomes
were retained. Type II probe bias was corrected using the BMIQ method as part of
the ChAMP pipeline61. Batch correction was performed using the ComBat algo-
rithm as part of the ChAMP pipeline62,63.
We identified differentially methylated sites between normal α− and β−cells, as
well as between α−like β−like and intermediate PanNETs, according to the
ChAMP pipeline64,65. To build phyloepigenetic trees, distances between samples
were calculated according to pearson correlation and the neighbour-joining tree
estimation was used within the ape (v5.3) R package66. The tSNE approach was
performed as implemented in the R package tsne using the following parameters:
perplexity= 50, max_iter= 500067.
We used the RnBeads pipeline68 for calculating cell-type contribution according
to the Houseman et al. method21. Sorted normal hematopoietic cell-type data
(granulocytes, CD4+ and CD8+ T cells, CD14+monocytes, CD19+ B cells,
CD56+ natural killer cells, neutrophils and eosinophils) were downloaded from
Reinius et al.23 (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/,
accession number: GSE35069). Sorted acinar, duct, alpha and beta pancreatic cell
DNA-methylation profiles were downloaded from Jäkel et al.20 (European
Genome-Phenome Archive, https://ega-archive.org/, accession number:
EGAS00001002533). DNA-methylation data for sorted normal pancreatic
fibroblast cells were downloaded from Xiao et al.22 (Gene Expression Omnibus,
http://www.ncbi.nlm.nih.gov/geo/, accession number: GSE80369). Marker selection
was performed by screening 10,000 CpG positions and the final number of selected
cell-type markers was set to 500 (as for default).
Consensus clustering was performed following the ConsensusClusterPlus
pipeline (maxK= 20, reps= 1000, pItem= 0.8, pFeature= 1 and distance=
pearson)69. Samples were clustered according to the hierarchical clustering
algorithm, ward.D2 method was used for inner linkage and average method was
used for the final linkage.
Based on genomic position, the 450 K probes were annotated with the
chromatin state, as assigned to normal pancreatic islets (obtained from the
integration of ATAC-Seq, DNAme and ChIP-seq data)26. Probes associated with
the cell-specific transcription factor (TF) checkpoints and associated to the
epigenetic states “closed weak enhancer”, “lowly-methylated weak enhancer”,
“open weak enhancer”, “closed strong enhancer”, “open strong enhancer”, “genic
enhancer”, “insulator” and “polycomb repressed states” were included for looking
at the specific TF-checkpoint methylation. Enhancer regions were associated to the
nearest gene in the genome using the GenomicRanges R package70.
Known Imprinting Control Regions (ICRs) were retrieved from WAMIDEX
and igc.otago.ac.nz (extended annotations reported in A-GEOD-18809 - Illumina
HumanMethylation450 BeadChip (v1.2, extended annotation)).
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Next-generation sequencing. We sequenced MEN1, DAXX and ATRX genes by
semi-conductive sequencing using two Ion Torrent AmpliSeq NGS custom made
panels (Life Technologies), one for ATRX and one for MEN1 and DAXX, cov-
ering whole protein-coding exons. Protein-coding exons were amplified by
multiplex polymerase chain reaction using two pools designed by the Ion
AmpliSeq Designer and the Ion AmpliSeq Library kit 2.0 according to the
manufacturer’s recommendations (Life Technologies). Template preparation
was performed using the Ion Chef System. Sequencing was performed using the
Ion S5. The Torrent Suite 5.10 platform was used for sequence alignment with
the hg19 human genome reference. Variant calling was performed with the
variant caller and the IonReporter 5.10 software (Life Technologies). The cov-
erage depth was sufficient (quality criteria for a sample to be analysed was
minimum 500 reads). The 80 ICGC samples were sequenced by whole-genome
sequencing (WGS) within the Scarpa et al. study47.
Copy-number aberration analysis. Genome-wide CNAs were inferred from
HM450 signal intensities using the Conumee R package71. Chromosome bins
and segments were measured (bin size: 50,000 to 5,000,000 bp; minimum
number of probes per bin: 15). CNA profile zero-threshold was manually
adjusted according to FISH results for the UB-UCL cohort (FISH for chr4 and
chr17 was performed for detecting gains, FISH for MEN1 and chr11 was used for
detecting losses; see Supplementary Fig. 3a–d). Zero-threshold of the CNA
profiles obtained from the ICGC cohort was manually adjusted according to the
results obtained from Scarpa et al.47. Copy number (CN) of each chromosomal
arm for each tumour was obtained calculating the median of the relative copy-
number bins. Arm level copy-number data were clustered using Ward’s method,
Euclidean distance.
Statistical analysis and graphic representation. Statistical analysis and graphical
representations were performed within the R environment (v. 3.5.0)72. Specific
packages used in the study and parameters selected are mentioned in the relative
method chapters. For disease free survival analysis, the “survival” and “survminer”
packages were used73,74.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its supplementary data and figures. The datasets generated during the
current study (UB-UCL cohort) are available in the ArrayExpress repository (EMBL-EBI,
https://www.ebi.ac.uk/arrayexpress/, accession number: E-MTAB-7924). The datasets
analysed during the current study (ICGC cohort) are available in the ICGC repository
(ICGC, https://icgc.org/, projects: PAEN-AU and PAEN-IT). The datasets of sorted
normal hematopoietic cells are available in the GEO repository (Gene Expression
Omnibus, http://www.ncbi.nlm.nih.gov/geo/, accession number: GSE35069). The
datasets of sorted acinar, duct, alpha and beta pancreatic cells are available in the EGA
repository (European Genome-Phenome Archive, https://ega-archive.org/, accession
number: EGAS00001002533). The datasets of sorted normal pancreatic fibroblastic cells
are available in the GEO repository (Gene Expression Omnibus, http://www.ncbi.nlm.
nih.gov/geo/, accession number: GSE80369). Chan et al.7 dataset is available in the GEO
repository (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/, accession
number: GSE117852).
Code availability
Details of publicly available software and packages used in the study are given in the
“Methods”. No custom code or mathematical algorithm that is deemed central to the
conclusions was used.
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